Monoclonal Antibody Market, By Source Type (Murine Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, and Fully Human Monoclonal Antibodies), By Production Types, By Indication, By End-User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4139
|
Published Date
July 2025
|
Pages
301
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
The Monoclonal Antibody Market size was valued at US$ 250.28 Million in 2024, expanding at a CAGR of 11.92% from 2025 to 2032.
The Monoclonal Antibody Market encompasses the development, production, and commercialization of laboratory-engineered antibodies designed to specifically target antigens for use in diagnostics, therapeutics, and research. Driven by the rising prevalence of chronic conditions such as cancer, autoimmune disorders, and infectious diseases, the market has seen significant growth—more than 70% of biologic therapies currently in development are monoclonal antibody-based. Despite their effectiveness, the widespread adoption of monoclonal antibodies is hindered by high production costs and complex manufacturing processes, which often limit affordability and accessibility. However, advances in bioengineering, recombinant DNA technology, and personalized medicine are opening new pathways for the creation of more targeted, efficient, and patient-specific treatments.
Furthermore, the global research community continues to invest heavily in this field, with nearly 500 active clinical trials involving monoclonal antibodies recorded last year. The expanding use of these therapies across oncology, immunology, and infectious disease management positions the market for sustained growth, as innovation and investment steadily overcome existing challenges.
Monoclonal Antibody Market- Market Dynamics
Surging Chronic Disease Burden and Bioengineering Innovations to Drive Monoclonal Antibody Market Expansion
The rising prevalence of chronic diseases such as cancer and autoimmune disorders has significantly accelerated demand for monoclonal antibody therapies. According to the World Health Organization (WHO), cancer alone has been responsible for nearly 10 million deaths globally in recent years, underscoring the urgent need for targeted treatments. Advances in bioengineering have further propelled the market, enabling more precise targeting of disease-specific mechanisms and leading to improved therapeutic efficacy and patient outcomes. In the past five years, the U.S. Food and Drug Administration (FDA) has approved over 20 monoclonal antibody-based drugs, reflecting growing confidence in these therapies. Moreover, organizations like the National Institutes of Health (NIH) continue to increase funding for biologics research, supporting innovative clinical trials and broadening the scope of monoclonal antibody applications across a range of chronic and infectious diseases.
Monoclonal Antibody Market- Segmentation Analysis:
The Global Monoclonal Antibody Market is segmented on the basis of Source Type, Production Types, Indication, End-User, and Region.
The monoclonal antibody market is categorized into four segments based on Source Type: Murine Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, and Fully Human Monoclonal Antibodies. Among these, humanized monoclonal antibodies dominate the market due to their lower immunogenicity and enhanced patient tolerance, making them suitable for long-term therapeutic use in conditions such as cancer, autoimmune diseases, and infectious diseases. Fully human monoclonal antibodies are also gaining significant traction, particularly valued for their superior safety profiles and minimal immune system reactions. Chimeric monoclonal antibodies, which combine murine and human components, remain effective in targeting specific antigens but are associated with higher risks of immune responses, limiting their long-term use. Murine monoclonal antibodies, the earliest form developed, are now used less frequently in clinical applications due to their high immunogenicity, though they still play a role in preclinical research. According to the U.S. Food and Drug Administration (FDA), over 60% of newly approved therapeutic antibodies in recent years have been either humanized or fully human, reflecting a clear industry preference toward safer and more tolerable antibody formats.
In terms of Production Type, the market is divided into In Vivo and In Vitro methods. In vitro production leads the market owing to its advantages in scalability, process control, and batch consistency, which are critical for meeting the high demand for therapeutic monoclonal antibodies in a cost-effective and reproducible manner. It allows for production in bioreactors under defined conditions, ensuring quality and compliance with Good Manufacturing Practice (GMP) standards. In contrast, in vivo methods, which involve producing antibodies in live animals such as mice, are now less commonly used. These methods are typically reserved for specific research applications due to being more time-consuming, less scalable, and costlier compared to in vitro techniques. According to data from the National Institutes of Health (NIH), more than 80% of monoclonal antibody production for commercial and clinical use in the U.S. is now conducted via in vitro systems, highlighting the industry\'s shift toward more efficient and ethically preferred production technologies.
Monoclonal Antibody Market- Geographical Insights
The Monoclonal Antibody Market demonstrates notable regional variation, shaped by healthcare infrastructure, regulatory environments, and disease burden. North America leads the market, bolstered by strong federal support—such as the U.S. National Cancer Institute’s $7.3 billion annual budget allocation—to advance cancer research and biologic therapies. This financial backing, combined with cutting-edge biopharmaceutical R&D facilities, enables rapid development and regulatory approval of monoclonal antibody treatments. Europe closely follows, with the European Medicines Agency (EMA) streamlining the approval process for biologics and the EU investing over €1 billion under the Horizon Europe program to support research in immunotherapy and precision medicine. In Asia-Pacific, rising incidences of cancer and autoimmune diseases, along with increasing healthcare investments in countries like China, Japan, and India, are driving demand. Government-led initiatives such as China’s “Healthy China 2030” and India’s expansion of biologics under its Ayushman Bharat scheme further support market growth. Latin America and the Middle East are also progressing gradually due to expanding insurance coverage and growing awareness, though affordability and infrastructure limitations remain challenges in some areas. These global government initiatives reflect a coordinated push toward increasing access to monoclonal antibody therapies worldwide.
Monoclonal Antibody Market- Competitive Landscape:
The competitive landscape of the Monoclonal Antibody Market is marked by the strong presence of global biopharmaceutical companies that are actively investing in research and development to expand their therapeutic portfolios and maintain a competitive edge. Leading firms are increasingly collaborating with academic institutions, biotech startups, and government research bodies to accelerate innovation and shorten development timelines. A key focus area is the advancement of antibody engineering technologies, including bispecific antibodies, antibody-drug conjugates (ADCs), and Fc-engineered molecules, aimed at addressing complex and previously untreatable diseases.
Regulatory approvals from major authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a pivotal role in shaping market dynamics, acting as gatekeepers for commercial success and global expansion. Strategic partnerships, mergers, and licensing agreements are also widely used to enter new markets, share technological expertise, and optimize manufacturing capabilities. Amid rising competition, companies are prioritizing manufacturing efficiency and cost reduction to improve the accessibility and affordability of monoclonal antibody therapies. The growing emphasis on personalized medicine and immunotherapy has further intensified investments in targeted therapies that offer improved clinical outcomes.
Recent Developments:
- September 2023: KBI Biopharma launched SureMAB™, a next-generation monoclonal antibody development platform designed to accelerate the discovery and production of high-quality mAbs, enabling faster time-to-market for novel biologics across multiple therapeutic areas.
- April 2025: The FDA introduced a phased plan to phase out mandatory animal testing for monoclonal antibodies and other pharmaceuticals. The initiative promotes the use of human-relevant testing methods such as AI-driven models and organoid systems, aiming to improve drug development efficiency, safety, and ethical standards.
- March 2024: Roche Pharma India launched Vabysmo (faricimab), the world’s first bispecific monoclonal antibody approved for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The drug targets two disease pathways simultaneously, offering extended treatment intervals and enhanced vision outcomes for Indian patients.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MONOCLONAL ANTIBODY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie
- Alexion Pharmaceuticals
- Amgen
- Bayer Healthcare
- Biogen
- Bristol-Myers Squibb
- Celltrion
- Eli Lilly
- Genentech (Roche subsidiary)
- GlaxoSmithKline (GSK)
- Johnson & Johnson
- Merck & Co.
- Novartis
- Pfizer
- Regeneron Pharmaceuticals
- Roche
- Samsung Bioepis
- Sanofi
- Takeda Pharmaceutical
- UCB Pharma
- Others
GLOBAL MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE- MARKET ANALYSIS, 2019 - 2032
- Murine Monoclonal Antibodies
- Chimeric Monoclonal Antibodies
- Humanized Monoclonal Antibodies
- Fully Human Monoclonal Antibodies
GLOBAL MONOCLONAL ANTIBODY MARKET, BY PRODUCTION TYPES- MARKET ANALYSIS, 2019 - 2032
- In Vivo
- In Vitro
GLOBAL MONOCLONAL ANTIBODY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Cancer
- Breast cancer
- Colorectal cancer
- Lung cancer
- Ovarian cancer
- Others
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Rheumatoid Arthritis
- Multiple Sclerosis
- Psoriasis
- Crohn’s Disease
- Others
GLOBAL MONOCLONAL ANTIBODY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Pharmaceutical & Biotechnology Companies
GLOBAL MONOCLONAL ANTIBODY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Monoclonal Antibody Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Monoclonal Antibody Market Snippet by Source Type
2.1.2. Monoclonal Antibody Market Snippet by Production Types
2.1.3. Monoclonal Antibody Market Snippet by Indication
2.1.4. Monoclonal Antibody Market Snippet by End-User
2.1.5. Monoclonal Antibody Market Snippet by Country
2.1.6. Monoclonal Antibody Market Snippet by Region
2.2. Competitive Insights
3. Monoclonal Antibody Key Market Trends
3.1. Monoclonal Antibody Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Monoclonal Antibody Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Monoclonal Antibody Market Opportunities
3.4. Monoclonal Antibody Market Future Trends
4. Monoclonal Antibody Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Monoclonal Antibody Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Monoclonal Antibody Market Landscape
6.1. Monoclonal Antibody Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Monoclonal Antibody Market – By Source Type
7.1. Overview
7.1.1. Segment Share Analysis, By Source Type, 2024 & 2032 (%)
7.1.2. Murine Monoclonal Antibodies
7.1.3. Chimeric Monoclonal Antibodies
7.1.4. Humanized Monoclonal Antibodies
7.1.5. Fully Human Monoclonal Antibodies
8. Monoclonal Antibody Market – By Production Types
8.1. Overview
8.1.1. Segment Share Analysis, By Production Types, 2024 & 2032 (%)
8.1.2. In Vivo
8.1.3. In Vitro
9. Monoclonal Antibody Market – By Indication
9.1. Overview
9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
9.1.2. Cancer
9.1.2.1. Breast cancer
9.1.2.2. Colorectal cancer
9.1.2.3. Lung cancer
9.1.2.4. Ovarian cancer
9.1.2.5. Others
9.1.3. Autoimmune Diseases
9.1.4. Inflammatory Diseases
9.1.5. Infectious Diseases
9.1.6. Rheumatoid Arthritis
9.1.7. Multiple Sclerosis
9.1.8. Psoriasis
9.1.9. Crohn’s Disease
9.1.10. Others
10. Monoclonal Antibody Market – By End-User
10.1. Overview
10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
10.1.2. Hospitals
10.1.3. Diagnostic Laboratories
10.1.4. Research Institutes
10.1.5. Pharmaceutical & Biotechnology Companies
11. Monoclonal Antibody Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Monoclonal Antibody Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Monoclonal Antibody Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Monoclonal Antibody Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Monoclonal Antibody Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Monoclonal Antibody Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Monoclonal Antibody Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. AbbVie
12.2.2. Alexion Pharmaceuticals
12.2.3. Amgen
12.2.4. Bayer Healthcare
12.2.5. Biogen
12.2.6. Bristol-Myers Squibb
12.2.7. Celltrion
12.2.8. Eli Lilly
12.2.9. Genentech (Roche subsidiary)
12.2.10. GlaxoSmithKline (GSK)
12.2.11. Johnson & Johnson
12.2.12. Merck & Co.
12.2.13. Novartis
12.2.14. Pfizer
12.2.15. Regeneron Pharmaceuticals
12.2.16. Roche
12.2.17. Samsung Bioepis
12.2.18. Sanofi
12.2.19. Takeda Pharmaceutical
12.2.20. UCB Pharma
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
